

## Report Information

More information from: <https://www.marketresearchfuture.com/reports/fibromyalgia-treatments-market-1879>

# Fibromyalgia Treatments Market Research Report- Forecast To 2030

Report / Search Code: MRFR/Pharma/1347-HCR

Publish Date: March, 2023

[Request Sample](#)

Price	1-user PDF : \$ 4950.0	Enterprise PDF : \$ 7250.0
-------	------------------------	----------------------------

## Description:

### Global Fibromyalgia Treatment Market Research (MRFR Insights)

The fibromyalgia treatment market size is projected reach USD 1,414.9 million by 2030 at 4.20% CAGR during the forecast period 2022 to 2030. A musculoskeletal illness called fibromyalgia is distinguished by severe pain, frequently accompanied by sleep problems, exhaustion, mood fluctuations, and memory loss. Only three medications have currently been licensed specifically for the treatment of fibromyalgia. As a result, off-label products are used more frequently to control the disease. But it's anticipated that increased research and development in pain management will support the use of approved medications for the illness indication. For instance, 21 clinical studies are now being done to evaluate the various therapy options for fibromyalgia, according to clinicaltrials.gov.

### COVID-19 Impact Analysis

The abrupt breakout of COVID-19 in various countries has considerably impacted pharmaceutical businesses' income and operational capabilities. Due to the reduced number of patients seeking treatment for the illness due to the pandemic, a lesser-known and underdiagnosed indicator, the market has been negatively impacted. The primary actors' reorientation toward developing COVID-19 drugs and preventive vaccines has also impacted the supply and demand for fibromyalgia treatments.

### Fibromyalgia treatment market Dynamics

In the case of fibromyalgia, psychiatric illnesses are becoming more common, and post-traumatic stress disorders are also becoming more common. Globally dominant organizations are acquiring firms dealing with many products recalls keeping their market share. Conversely, favourable reimbursement policies and rising healthcare costs also drive the market.

### Market Drivers

- An increase in the prevalence of fibromyalgia

Several factors fuel the expansion of the global market. However, the primary factor projected to grow the market was the rise in fibromyalgia on a global scale. Around five million Americans who are 18 years of age or older and have fibromyalgia, according to the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), suffer from the condition. In addition, females make up between 80 and 90 percent of fibromyalgia patients. Additionally, it is anticipated that rising government measures to educate businesses and medical professionals about fibromyalgia have boosted the market.

### Market Restraints:

- Increased use of off-label and generic medications to curb the market growth

Only three medications are currently specifically licensed for the treatment of fibromyalgia. To treat the illness indication, off-label medications and generic antidepressants are now being used more frequently. Furthermore, Pfizer lost the ability to patent-protect Lyrica in June 2019. This patent expiration has adversely damaged the drug's market revenue. According to estimates, generic competition will impede market expansion in the foreseeable future.

### Market Opportunities:

- Market growth from strong pipeline products

Established firms with a monopoly on the market are actively involved in introducing cutting-edge fibromyalgia remedies to create or maintain their market position. Over the anticipated timeframe, the market is expected to develop due to forthcoming releases and authorizations that concentrate on treating fibromyalgia. Galcanezumab, a medication created by Eli Lilly and Company, is undergoing a phase 4 clinical trial as of January 2021. The medication is approved to treat migraine and cluster headaches, and it is anticipated to enter its crucial clinical end-stage for the treatment of fibromyalgia in December 2021.

### Fibromyalgia Treatment Market Segmentation

### Treatment Insights

Based on treatment, the fibromyalgia treatment market segmentation is antidepressants, antiepileptics, muscle relaxants, and others. The fibromyalgia treatment market growth was prominently high under the antiepileptic category in 2021. Anticonvulsants, usually antiepileptic medications, are frequently prescribed to treat epilepsy, but they have also been used to treat fibromyalgia. The FDA has approved the antiepileptic drug pregabalin for the treatment of fibromyalgia. Pregabalin blocks the release of P, norepinephrine, and glutamate, which may help fibromyalgia patients feel less pain. Depending on the patient's creatinine clearance, pregabalin must be begun at 75 mg twice daily and gradually increased to 225 mg twice daily. Daily doses of 450 mg, 300 mg, or 600 mg can lessen pain by more than 30% if the patient can bear the side effects of drowsiness, dry mouth, added weight, and edema. However, antidepressants are anticipated to be the fastest growing in the coming years. The signs of depression may be lessened with the aid of antidepressants. Additionally, they can help treat the seasonal affective disorder and social anxiety disorder. There is growing evidence that, to a limited extent, antidepressants are effective therapies for fibromyalgia. Antidepressants change specific neurotransmitters in the brain, and these same neurotransmitters play a role in fibromyalgia. One of the most popular forms of treatment is amitriptyline and other tricyclic antidepressants (TCAs). Newer antidepressants have undergone thorough fibromyalgia testing since they are better tolerated than tricyclics. Instead of acting as an antidepressant, cyclobenzaprine, a tricyclic substance that varies from amitriptyline only by one double bond, relaxes the muscles.

## End User Insights

The fibromyalgia treatment market segmented, based on end users, is hospitals and clinics. In 2021, clinics accounted for the largest market share of the global market. Any pharmacy that dispenses, stocks, or sells prescription drugs to the general public is considered a retail pharmacy. Consumers can pick up their medication at a retail pharmacy without acquiring a prescription. Customers have direct contact with the retailer. A reputable company that sells medicines and related goods is a retail pharmacy. However, the hospital category is estimated to register the highest growth rate during the forecast period. These include residential care institutions, hospitals, outpatient clinics, drug addiction treatment centers, poison control centers, and drug resource centers. The job involves choosing, preparing, storing, compounding, and dispensing drugs for patients in a medical setting.

## Global Fibromyalgia Treatment Market Share, by Region, 2021 (%)

### Fibromyalgia Treatment Market Share, by Region, 2021 (%)

#### Fibromyalgia treatment market Overview, by Region

By region, the fibromyalgia treatment market has been divided into North America, Europe, Asia-Pacific, and the Rest of the World. North America accounted for the most extensive market share. Europe will exhibit the highest CAGR during the forecast period.

## North America

North America dominated the market share in 2021. The increase in fibromyalgia diagnoses and prevalence, along with the expanded availability of cutting-edge, FDA-approved medications to treat the condition, is responsible for the development. According to the American Chronic Pain Association (2017), fibromyalgia affects between 2 and 4% of Americans. Additionally, it is anticipated that the market will grow throughout the projection period due to key rivals' increased focus on launching novel pharmaceuticals in the North American area. The region's market is anticipated to increase due to rising healthcare costs and expanding healthcare infrastructure. The market will probably expand as fibromyalgia becomes a more well-recognized condition. In addition, expanding biopharmaceutical industries are concentrating on drugs, over-the-counter drug demand is up, and the rising number of instances that resulted in rising drug demand would affect the region's market growth.

## Europe

Europe accounted for the second-largest market share in 2021. Numerous factors, including the increased incidence of fibromyalgia, contributed to the market growth in Europe. Additionally, the product introductions and the absence of fibromyalgia treatments fueled market expansion in the ensuing years. Additionally, it is projected that an increase in healthcare spending by the European Commission has spurred regional expansion.

## Fibromyalgia treatment market Competitive Landscape

The market includes tier-1, tier-2, and local players. Significant competition can be seen in the global market, which is dominated by major companies like Pfizer, Inc., Eli Lilly and Company, and Allergan. These major players primarily use mergers and acquisitions as well as creative product launches to expand their client base. Players like Tonix Pharmaceuticals and Teva are significant rivals in the market due to their robust pipeline of goods. For instance, in February 2022, Wet cupping therapy (WCT), a new treatment for fibromyalgia, is being studied by Karabuk University in Turkey in partnership with Saglik Bilimleri University and SULEYMAN ERSOY.

Prominent players in the fibromyalgia treatment market research include Pfizer, AstraZeneca, GlaxoSmithKline, Astellas Pharma, F. Hoffmann-La Roche AG, SANOFI, and Johnson & Johnson Services Inc., among others.

## Scope of the Fibromyalgia treatment market Report

### Treatment Outlook

- Antidepressants
- Antiepileptic
- Muscle Relaxants
- Others

### End User Outlook

- Hospital
- Clinic

### Region Outlook

- North America

- US
  - Canada
  - Mexico
- Europe
  - UK
  - Germany
  - France
  - Italy
  - Spain
  - Rest of Europe
- Asia-Pacific
  - China
  - India
  - Japan
  - Australia and New Zealand
  - Rest of Asia-Pacific
- Rest of the World
  - South America
  - Middle East
  - Africa

### **Objectives of the Study**

The objectives of the study are summarized in 5 stages. They are as mentioned below:

#### **Fibromyalgia treatment market Forecast & Size:**

To identify and estimate the market size for the fibromyalgia treatment market report segmented by treatment and end user by value (in US dollars). Also, to understand the consumption/ demand created by consumers of fibromyalgia treatment market forecast between 2022 and 2030

#### **Market Landscape and Trends:**

To identify the fibromyalgia treatment market growth and infer the drivers, restraints, opportunities, and challenges.

#### **Market Influencing Factors:**

To find out the factors which are affecting the fibromyalgia treatment market size

#### **Impact of COVID-19:**

To identify and understand the various factors involved in the market affected by the pandemic

#### **Company Profiling:**

To provide a detailed insight into the major companies operating in the market. The profiling will include the financial health of the company in the past 2-3 years with segmental and regional revenue breakup, product offering, recent developments, SWOT analysis, and key strategies.

#### **Intended Audience**

- Fibromyalgia treatment producers
- Raw material suppliers
- Retailers, wholesalers, and distributors
- Governments, associations, and industrial bodies
- Pharma companies

## Table of Content:

Contents	
Table of Contents:	
Chapter 1. Report Prologue	
Chapter 2. Market Introduction	
2.1 Definition	
2.2 Scope of the Study	
2.2.1 Research Objective	
2.2.2 Assumptions	
2.2.3 Limitations	
Chapter 3. Research Methodology	
3.1 Introduction	
3.2 Primary Research	
3.3 Secondary research	
3.4 Market Size Estimation	
Chapter 4. Market Dynamics	
4.1 Drivers	
4.2 Restraints	
4.3 Opportunities	
4.4 Challenges	
4.5 Macroeconomic Indicators	
4.6 Technology Trends & Assessment	
Chapter 5. Market Factor Analysis	
5.1 Porter's Five Forces Analysis	
5.1.1 Bargaining Power of Suppliers	
5.1.2 Bargaining Power of Buyers	
5.1.3 Threat of New Entrants	
5.1.4 Threat of Substitutes	
5.1.5 Intensity of Rivalry	
5.2 Value Chain Analysis	
5.3 Investment Feasibility Analysis	
5.4 Pricing Analysis	
Chapter 6. Global Fibromyalgia Treatment Market, by Diagnosis	
6.1 Introduction	
6.2 Laboratory Evaluation	
6.2.1 Market Estimates & Forecast, 2017–2023	
6.3 Presence of Central Sensitization	
6.3.1 Market Estimates & Forecast, 2017–2023	
Chapter 7. Global Fibromyalgia Treatment Market, by Treatment	
7.1 Introduction	
7.2 Symptomatic Treatment	
7.2.1 Market Estimates & Forecast, 2017–2023	
7.3 Targeted Treatment	
7.3.1 Market Estimates & Forecast, 2017–2023	
Chapter 8. Global Fibromyalgia Treatment Market, by End-User	
8.1 Introduction	
8.2 Hospital	
8.2.1 Market Estimates & Forecast, 2017–2023	
8.3 Clinics	
8.3.2 Market Estimates & Forecast, 2017–2023	
8.4 Diagnostic Centers	
8.4.1 Market Estimates & Forecast, 2017–2023	
8.5 Others	
8.5.2 Market Estimates & Forecast, 2017–2023	
Chapter 9. Global Fibromyalgia Treatment Market, by Region	
9.1 Introduction	
9.2 Americas	
9.2.1 North America	
9.2.1.1 U.S.	
9.2.1.1 Canada	
9.2.2 South America	
9.3 Europe	
9.3.1 Western Europe	
9.3.1.1 Germany	
9.3.1.2 France	
9.3.1.3 Italy	
9.3.1.4 Spain	
9.3.1.5 U.K.	
9.3.1.6 Rest of Western Europe	
9.3.2 Eastern Europe	
9.4 Asia Pacific	
9.4.1 Japan	
9.4.2 China	
9.4.3 India	
9.4.4 Australia	
9.4.5 Republic of Korea	
9.4.6 Rest of Asia Pacific	
9.5 The Middle East & Africa	
9.5.1 United Arab Emirates	
9.5.2 Saudi Arabia	
9.5.3 Oman	
9.5.4 Kuwait	
9.5.5 Qatar	
9.5.6 Rest of the Middle East & Africa	
Chapter 10. Company Landscape	
10.1 Introduction	
10.2 Market Share Analysis	
10.3 Key Development & Strategies	
10.3.1 Key Developments	
Chapter 11. Company Profiles	
11.1 Pfizer	
11.1.1 Company Overview	

11.1.2	Types Overview
11.1.3	Financials
11.1.4	SWOT Analysis
11.2	GlaxoSmithKline
11.2.1	Company Overview
11.2.2	Types Overview
11.2.3	Financial Overview
11.2.4	Key Developments
11.2.5	SWOT Analysis
11.3	AstraZeneca
11.3.1	Company Overview
11.3.2	Types Overview
11.3.3	Financial Overview
11.3.4	Key Development
11.3.5	SWOT Analysis
11.4	F. Hoffmann-La Roche AG
11.4.1	Company Overview
11.4.2	Types/Business Segment Overview
11.4.3	Financial Overview
11.4.4	Key Development
11.4.5	SWOT Analysis
11.5	Astellas Pharma
11.5.1	Company Overview
11.5.2	Types Overview
11.5.3	Financial overview
11.5.4	Key Developments
11.6	Johnson & Johnson Services, Inc.
11.6.1	Company Overview
11.6.2	Types Overview
11.6.3	Financial Overview
11.6.4	Key Developments
11.7	SANOFI
11.7.1	Overview
11.7.2	Types Overview
11.7.3	Financials
11.7.4	Key Developments
11.7.5	SWOT Analysis
11.8	Others

## Chapter 12 MRFR Conclusion

12.1	Key Findings
12.1.1	From CEO's View Point
12.1.2	Unmet Needs of the Market
12.2	Key Companies to Watch
12.3	Prediction of Fibromyalgia Treatment industry

## Chapter 13 Appendix

### LIST OF TABLES

Table 1	Fibromyalgia Treatment Industry Synopsis, 2017–2023
Table 2	Fibromyalgia Treatment Market Estimates and Forecast, 2017–2023, (USD Million)
Table 3	Fibromyalgia Treatment Market, by Region, 2017–2023, (USD Million)
Table 4	Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 5	Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 6	Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 7	North America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 8	North America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 9	North America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 10	US Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 11	US Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 12	US Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 13	Canada Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 14	Canada Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 15	Canada Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 16	South America Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 17	South America Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 18	South America Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 19	Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 20	Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 21	Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 22	Western Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 23	Western Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 24	Western Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 25	Eastern Europe Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 26	Eastern Europe Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 27	Eastern Europe Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 28	Asia Pacific Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 29	Asia Pacific Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 30	Asia Pacific Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)
Table 31	Middle East & Africa Fibromyalgia Treatment Market, by Diagnosis, 2017–2023, (USD Million)
Table 32	Middle East & Africa Fibromyalgia Treatment Market, by Treatment, 2017–2023, (USD Million)
Table 33	Middle East & Africa Fibromyalgia Treatment Market, by End-User, 2017–2023, (USD Million)

### LIST OF FIGURES

Figure 1	Research Process
Figure 2	Segmentation for Fibromyalgia Treatment Market
Figure 3	Segmentation Market Dynamics for Fibromyalgia Treatment Market
Figure 4	Global Fibromyalgia Treatment Market Share, by Diagnosis, 2016
Figure 5	Global Fibromyalgia Treatment Market Share, by Treatment, 2016
Figure 6	Global Fibromyalgia Treatment Market Share, by End-User, 2016
Figure 7	Global Fibromyalgia Treatment Market Share, by Region, 2016
Figure 8	North America Fibromyalgia Treatment Market Share, by Country, 2016
Figure 9	Europe Fibromyalgia Treatment Market Share, by Country, 2016
Figure 10	Asia Pacific Fibromyalgia Treatment Market Share, by Country, 2016
Figure 11	Middle East & Africa Fibromyalgia Treatment Market Share, by Country, 2016

Figure 12 Global Fibromyalgia Treatment Market: Company Share Analysis, 2016 (%)  
Figure 13 Pfizer: Key Financials  
Figure 14 Pfizer Segmental Revenue  
Figure 15 Pfizer: Geographical Revenue  
Figure 16 GlaxoSmithKline: Key Financials  
Figure 17 GlaxoSmithKline: Segmental Revenue  
Figure 18 GlaxoSmithKline: Geographical Revenue  
Figure 19 AstraZeneca: Key Financials  
Figure 20 AstraZeneca: Segmental Revenue  
Figure 21 AstraZeneca: Geographical Revenue  
Figure 22 F. Hoffmann-La Roche AG: Key Financials  
Figure 23 F. Hoffmann-La Roche AG: Segmental Revenue  
Figure 24 F. Hoffmann-La Roche AG: Geographical Revenue  
Figure 25 Astellas Pharma: Key Financials  
Figure 26 Astellas Pharma: Segmental Revenue  
Figure 27 Astellas Pharma Geographical Revenue  
Figure 28 Johnson & Johnson Services, Inc.: Key Financials  
Figure 29 Johnson & Johnson Services, Inc.: Segmental Revenue  
Figure 30 Johnson & Johnson Services, Inc.: Geographical Revenue  
Figure 31 SANOFI: Key Financials  
Figure 32 SANOFI: Segmental Revenue  
Figure 33 SANOFI: Geographical Revenue